Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.

Expert opinion on drug safety - 1 Apr 2017

Zhu Viola, Ou S H

Abstract excerpt

INTRODUCTION: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) may derive significant clinical benefit from targeted therapies against this driver mutation, but progression is virtually inevitable. Alectinib is a next-generation ALK inhibitor that provides a novel treatment option for this group of patients. Areas covered: In this review, we summarize the overall safety...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carbazoles
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gene Rearrangement

Share to Piperidines

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 28276856
DOI: 10.1080/14740338.2017.1299706

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.PMID 28276856Read ↗

Alectinib for advanced ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Alectinib for treatment of ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective change.Semantic proximity Read ↗

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.Semantic proximity Read ↗

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistanceSemantic proximity Read ↗

Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).Semantic proximity Read ↗

Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.Semantic proximity Read ↗

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer.Semantic proximity Read ↗

Case Report of Non–Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to AlectinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.